View printer-friendly version
« Back
February 16, 2005 10:01 a.m.
Teva To Broadcast Fourth Quarter 2004 Earnings Luncheon On The Web

Jerusalem, Israel, February 16, 2005 - In conjunction with Teva Pharmaceutical Industries Ltd.'s (Nasdaq:TEVA) Fourth Quarter 2004 Luncheon, we invite our friends around the globe, who are unable to attend, in person, to listen to the event, which will be broadcast live over the Internet on Thursday, February 17, 2005 at 12:45 p.m. Eastern Standard Time.

What: Teva's Fourth Quarter 2004 Luncheon (Audio & Slides)

When: Thursday, February 17, 2005 @ 12:45 p.m. EST

Where: www.tevapharm.com or

http://www.vcall.com/CoLocated.asp?ID=90596&urlID=93961&playerID=1


How: Live over the Internet -- Simply log on to the web at the address above and
register for the event (approx. 10 minutes before)

If you are unable to participate during the live webcast, the call will be archived on Teva's website at: www.tevapharm.com. To access the replay, go to Investor Relations and click on Conference Calls.

Contact: Dorit Meltzer, ++ 972-3-926-7554
Kevin Mannix, (215) 591-8912

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from
http://www.microsoft.com/windows/windowsmedia/EN/default.asp
and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an e-mail to webcast@multivu.com .



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.